This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Welcome to Nimenrix

Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neiserria meningitidis serogroups A, C, W-135 and Y1

Clinic support material

Order your clinic support materials to inform consumers about meningococcal disease.

Order material

eLearning modules

Access E-Learning modules for our vaccines

Access now

Ask Pfizer

Contact our Pfizer Vaccines UK team

Contact Us

Nimenrix dosing and administration

Learn more

Nimenrix in the routine immunisation programme

Learn more

Nimenrix for travel

Learn more

  1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here.
PP-NIM-GBR-0246. March 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020